Medicure Inc. - Product Pipeline Review - Q1 2011

Global Markets Direct, June 2011, Pages: 39

Medicure Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Medicure Inc. - Product Pipeline Review - Q1 2011” provides data on the Medicure Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Medicure Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Medicure Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Medicure Inc. - Brief Medicure Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Medicure Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Medicure Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Medicure Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Medicure Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Medicure Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Medicure Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Medicure Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Medicure Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Medicure Inc. Snapshot
Medicure Inc. Overview
Key Information
Key Facts
Medicure Inc. – Research and Development Overview
Key Therapeutic Areas
Medicure Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Medicure Inc. – Pipeline Products Glance
Medicure Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Medicure Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Medicure Inc. – Drug Profiles
MC-4232
Product Description
Mechanism of Action
R&D Progress
TARDOXAL
Product Description
Mechanism of Action
R&D Progress
MC-4262
Product Description
Mechanism of Action
R&D Progress
MC-45301
Product Description
Mechanism of Action
R&D Progress
MC-45308
Product Description
Mechanism of Action
R&D Progress
MC-5723
Product Description
Mechanism of Action
R&D Progress
MC-45228
Product Description
Mechanism of Action
R&D Progress
MC-45403
Product Description
Mechanism of Action
R&D Progress
MC45350
Product Description
Mechanism of Action
R&D Progress
NHE Inhibitor
Product Description
Mechanism of Action
R&D Progress
Medicure Inc. – Pipeline Analysis
Medicure Inc. – Pipeline Products by Therapeutic Class
Medicure Inc. - Pipeline Products By Target
Medicure Inc. – Pipeline Products by Route of Administration
Medicure Inc. – Pipeline Products by Molecule Type
Medicure Inc. - Dormant Projects
Medicure Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
MC-1
Medicure Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Medicure Inc., Deals Summary, 2004 to 2011
Medicure Inc. Detailed Deal Summary
Equity Offering
Medicure Completes Private Placement Of $26 Million
Medicure Announces Private Placement Of $3 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Medicure Inc. – Pipeline by Therapy Area and Indication, 2011
Medicure Inc. – Pipeline by Stage of Development, 2011
Medicure Inc. – Monotherapy Products in Pipeline, 2011
Medicure Inc. - Phase II, 2011
Medicure Inc. - Phase I, 2011
Medicure Inc. - Pipeline By Therapeutic Class, 2011
Medicure Inc. - Pipeline By Target, 2011
Medicure Inc. – Pipeline By Route of Administration, 2011
Medicure Inc. – Pipeline By Molecule Type, 2011
Medicure Inc. - Dormant Developmental Projects, 2010
Medicure Inc. - Discontinued Pipeline Products, 2010
Medicure Inc., Subsidiaries
Medicure Inc., Deals Summary, 2004 to 2011

List of Figures
Medicure Inc. – Pipeline by Therapy Area and Indication, 2011
Medicure Inc. – Pipeline by Stage of Development, 2011
Medicure Inc. – Monotherapy Products in Pipeline, 2011
Medicure Inc. – Pipeline By Therapeutic Class, 2011
Medicure Inc. - Pipeline By Target, 2011
Medicure Inc. – Pipeline By Route of Administration, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• Ixia - Company Analysis
• eBay - Strong Execution
• Accenture - Profile - US
• Dell - Profile - US